Current and future treatment options for managing hyperkalemia

Kidney International Supplements

Volumn 6, Issue 1, 2016, Pages 29-34

  Weir, Matthew R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

chronic kidney disease; congestive heart failure; hyperkalemia; patiromer; RAAS inhibitors; ZS 9

Indexed keywords

EID: 84964502092     PISSN: 21571724     EISSN: 21571716     Source Type: Journal    
DOI: 10.1016/j.kisu.2016.01.005     Document Type: Review

References (40)

1. P.A. Gabow, and L.N. Peterson Disorders of potassium metabolism R.W. Schrier, Renal and Electrolyte Disorders 14th edition 1992 Little, Brown and Company New York, NY 231 285
2. F.J. Gennari, and J.J. Cohen Role of the kidney in potassium homeostasis: lessons from acid-base disturbances Kidney Int 8 1975 1 5
3. D.H. Ellison, H. Velazquez, and F.S. Wright Mechanisms of sodium, potassium, and chloride transport by the renal distal tubule Miner Electrolyte Metab 13 1987 422 432
4. R.A. DeFronzo Hyperkalemia and hyporeninemic hypoaldosteronism Kidney Int 17 1980 118 134
5. B.F. Palmer Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system N Engl J Med 351 2004 585 592
6. B.F. Palmer A physiologic-based approach to the evaluation of a patient with hyperkalemia Am J Kidney Dis 56 2010 387 393
7. R.A. DeFronzo, M. Bia, and D. Smith Clinical disorders of hyperkalemia Annu Rev Med 33 1982 521 554
8. M. Epstein Hyperkalemia constitutes a constraint for implementing renin-angiotensin-aldosterone inhibition: the widening gap between mandated treatment guidelines and the real-world clinical arena Kidney Int Suppl 6 2016 20 28
9. M. Epstein, N.L. Reaven, S.E. Funk, and et al. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin aldosterone system inhibitors Am J Manag Care 21 2015 S212 S220
10. J.N. An, J.P. Lee, H.J. Jeon, and et al. Severe hyperkalemia requiring hospitalization: predictors of mortality Crit Care 16 2012 R225
11. L.M. Einhorn, M. Zhan, V.D. Hsu, and et al. The frequency of hyperkalemia and its significance in chronic kidney disease Arch Intern Med 169 2009 1156 1162
12. N. Jain, S. Kotla, B.B. Little, and et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease Am J Cardiol 109 2015 1510 1513
13. J. Khanagavi, T. Gupta, W.S. Aronow, and et al. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes Arch Med Sci 10 2014 251 257
14. P.A. McCullough, T.M. Beaver, E. Bennett-Guerrero, and et al. Acute and chronic cardiovascular effects of hyperkalemia: new insights into prevention and clinical management Rev Cardiovasc Med 15 2014 11 23
15. M.J. Elliott, P.E. Ronksley, C.M. Clase, and et al. Management of patients with acute hyperkalemia CMAJ 182 2010 1631 1635
16. L.S. Weisberg Management of severe hyperkalemia Crit Care Med 36 2008 3246 3251
17. UK Renal Association. Clinical practice guidelines: treatment of acute hyperkalaemia in adults - March 2014. Available at: http://www.renal.org/docs/default-source/guidelines-resources/joint-guidelines/treatment-of-acute-hyperkalaemia-in-adults/hyperkalaemia-guideline - -march-2014.pdf?sfvrsn=2. Accessed January 11, 2016.
18. B.A. Mahoney, W.A. Smith, D.S. Lo, and et al. Emergency intervention for hyperkalaemia Cochrane Database Syst Rev 18 2005 CD003235
19. P.P. Ahee, and A.V. Crowe The management of hyperkalaemia in the emergency department J Accid Emerg Med 17 2000 188 191
20. M.J. Nyirenda, J.I. Tang, P.L. Padfield, and J.R. Seckl Hyperkalaemia BMJ 339 2009 b4114
21. A. Alfonzo, C. Isles, C. Geddes, and C. Deighan Potassium disorders - clinical spectrum and emergency management Resuscitation 70 2006 10 25
22. T.R. Davis, B.A. Young, M.S. Eisenberg, and et al. Outcome of cardiac arrests attended by emergency medical services staff at community outpatient dialysis centers Kidney Int 73 2008 933 939
23. M. Ostermann Cardiac arrests in haemodialysis patients: an ongoing challenge Kidney Int 73 2008 907 908
24. K. Ray, S. Dorman, and R. Watson Severe hyperkalaemia due to the concomitant use of salt substitutes and ACE inhibitors in hypertension: a potentially life threatening interaction J Hum Hypertens 13 1999 717 720
25. C.J. Doorenbos, and C.G. Vermeij Danger of salt substitutes that contain potassium in patients with renal failure BMJ 326 2003 35 36
26. L. Lepage, A.C. Dufour, J. Doiron, and et al. Randomized clinical trial of sodium polystyrene sulfonate for the treatment of mild hyperkalemia in CKD Clin J Am Soc Nephrol 10 2015 2136 2142
27. R.H. Sterns, M. Rojas, P. Bernstein, and S. Chennupati Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? J Am Soc Nephrol 21 2010 733 735
28. C.P. Kovesdy Management of hyperkalaemia in chronic kidney disease Nat Rev Nephrol 10 2014 653 662
29. Z. Harel, S. Harel, P.S. Shah, and et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review Am J Med 126 2013 264.e9 264.e24
30. J.M. Buysse, I.Z. Huang, and B. Pitt PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016 Future Cardiol 8 2012 17 28
31. US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate) powder: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) - September 2009. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186845.htm. Accessed September 15, 2015.
32. M.A. Watson, T.P. Baker, A. Nguyen, and et al. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study Am J Kidney Dis 60 2012 409 416
33. M.R. Weir, G.L. Bakris, D.A. Bushinsky, et al. for the OPAL-HK Investigators Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors N Engl J Med 372 2015 211 221
34. G.L. Bakris, B. Pitt, M.R. Weir, and et al. Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial JAMA 314 2015 151 161
35. D.A. Bushinsky, G.H. Williams, B. Pitt, and et al. Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia Kidney Int 88 2015 1427 1433
36. M. Epstein, and M.D. Lifschitz Potassium homeostasis and dyskalemias: the respective roles of renal, extrarenal, and gut sensors in potassium handling Kidney Int Suppl 6 2016 7 15
37. F. Stavros, A. Yang, A. Leon, M. Nuttall, and H.S. Rasmussen Characterization of structure and function of ZS-9, a K+ selective ion trap PLoS One 9 2014 e114686
38. M. Kosiborod, H.S. Rasmussen, P. Lavin, and et al. Effect of sodium zirconium cyclosilicate on potassium lowering for 28 days among outpatients with hyperkalemia: the HARMONIZE randomized clinical trial JAMA 312 2014 2223 2233
39. D.K. Packham, H.S. Rasmussen, P.T. Lavin, and et al. Sodium zirconium cyclosilicate in hyperkalemia N Engl J Med 372 2015 222 231
40. M. Epstein Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism Lancet Diabetes Endocrinol 3 2015 993 1003